SHORT COMMUNICATIONS this open test was negative, we proceeded to patch test with FlexidoJ® spray (as is) and its individual components, and with a non-steroidal anti-inflammatory drug (NSAID) series. The 2nd patient was also tested with piroxicam.We found strongly positive reactions in both patients to FlexidoJ® spray (as is) and to fepradinol 0. I%, 0.5%, I% and 5% aq., with a + + + reaction to the highest concentration. 20 healthy controls patch tested with fepradinol 5% aq. were all negative.The 1st patient was also positive to nickel, but otherwise both patients were entirely negative to the other components of FlexidoJ® spray (benzyl alcohol, essence and propylene glycol) and all other NSAIDs tested (salicylic acid, thiosalicylic acid, indomethacin, paracetamol, benzydamine, piketoprofen, ketoprofen, ibuprofen, naproxen, phenylbutazone, bufexamac and, in Case no. 2. only, piroxicam).
DiscussionAlthough there are many reports (1-5) of contact allergy to various topical NSAIDs, we believe that these are the first 2 case reports of allergic contact Contact Dermatitis 1992: 27: 267 dermatitis from fepradinol. Fepradinol is not chemically or functionally related to any other NSAID and the absence of cross-sensitivity in our patients was therefore expected. We think that fepradinol should not be tested above I% aq., because 5% aq. produced too strong a positive reaction.
e14033 Background: In 2015, in our outpatient clinic, we implemented a breast cancer interdisciplinary team with the goal of identifying risk factors for chemotherapy delay. Evaluation of individual cases and care plans were made by a medical oncologist, clinical pharmacologist, psychologist, dietician and oncology nurse. Methods: 81 patients with breast cancer in neoadjuvant/adjuvant chemotherapy were prospectively evaluated from July 2018 until July 2019 for clinical risk: age, anthracyckine use, presence of symptoms grade >3, ASGPPP questionnaire for nutritional risk, psychological risk for pre existent issues or induce by treatment and IRPO questionnaire for screening, nursing evaluation for comunication, organization and understanding issues, and pharmacologist evaluation of polypharmacy and unknown drugs or routine use. Results: Of 81 patients evaluated and had finish treatment, 55 pts (67.9%) received adjuvant chemotherapy. Median age was 57.9 years (range:29-90.6y). We defined as risk factors for delay chemotherapy treatment: anthracycline-based chemotherapy (9.34 vs 2.58 d p:0.002), psychological risk (both risks combined) (8.1 vs 4.7 p:0.047), comunication, organization and understanding issues (15.25 vs 5.83 d p: 0.004), and unknown drugs that routinely uses (11 vs 5.34d p:0.012). Patients who needed extra nutritional and psychological appointment had greater delay in chemotherapy (Dietician: 9.636 vs 4.7 d P:0.01; Psyc: 9.1 vs 4.2d p:0.008). Conclusions: The chemotherapy scheme, psychological risk, difficulty in understanding and organizing, and unaware of the drugs used routinely uses were high risk factors for delayed chemotherapy and these patients should be handled more carefully.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.